Search results

  1. forestglip

    Trial Report Plasma cell targeting with the anti-CD38 antibody daratumumab in ME/CFS -a clinical pilot study, 2025, Fluge et al

    I'd say the top four look pretty good. The paper was saying participants 2 (red) and 5 (green) were also responders based on questionnaires, with participant 5 not sustaining the improvement. Participant 2's (red) subjective improvement does seem really close to the other four sustained...
  2. forestglip

    Trial Report Plasma cell targeting with the anti-CD38 antibody daratumumab in ME/CFS -a clinical pilot study, 2025, Fluge et al

    It's kind of hard to make out what's going on in the chart of steps vs. time (fig. 5A) because they all start from a wide variety of baseline steps. So I plotted change in steps from start of study to make it easier to see the timeline of improvement. Each position on the x-axis is an average...
  3. forestglip

    Haptoglobin phenotypes and structural variants associate with post-exertional malaise and cognitive dysfunction in [ME], 2025, Moezzi, Moreau et al

    I don't know. It'd be great to have large effect sizes, but the next best thing is at least being significant. Until we have a reason to forget about it, like a study that finds the opposite, I think it's fine to speculate about. Small but significant can still be biologically meaningful. You...
  4. forestglip

    Haptoglobin phenotypes and structural variants associate with post-exertional malaise and cognitive dysfunction in [ME], 2025, Moezzi, Moreau et al

    No, it'd be log2(x mg/dL) = [number on y axis] So reverse the calculation. To go from the y axis to the real measurement, you do 2^number. So a value of 8 on the chart equals 2^8=256 mg/dL. I think it's normally done when the data is skewed. Taking the log makes it more normally distributed...
  5. forestglip

    Longitudinal Neurochemical Aftermath from Post-COVID [CFS/ME] Sequalae in the Posterior Cingulate Gyrus, 2025, Hye Bin Yoo

    It feels like the abstract is lacking in detail. What do they mean by "neuronal activity" or "metabolic information"?
  6. forestglip

    Can any antivirals kill/inhibit EBV (Epstein Barr Virus)?

    Could you explain more about why it's implausible?
  7. forestglip

    The Role of CYP3A in Health and Disease, Klyushova, et al, 2022

    Why would the body keep thinking there are toxins?
  8. forestglip

    Preprint Initial findings from the DecodeME genome-wide association study of myalgic encephalomyelitis/chronic fatigue syndrome, 2025, DecodeMe Collaboration

    Ok thanks. How did you select traits to highlight? For example, BTN3A2 has 97 traits, some with even lower p values than some of the traits in your table, such as height or teeth issues.
  9. forestglip

    Preprint Initial findings from the DecodeME genome-wide association study of myalgic encephalomyelitis/chronic fatigue syndrome, 2025, DecodeMe Collaboration

    Can you give more detail for how you used to decodeme data to get these lists of traits? Search for genes? Variants? Ranges?
  10. forestglip

    Defining a long COVID ‘expotype’ within the P4O2 COVID-19 study, 2025, Holtjer et al

    I wasn't sure what "blue space" meant. Wikipedia
  11. forestglip

    Defining a long COVID ‘expotype’ within the P4O2 COVID-19 study, 2025, Holtjer et al

    Defining a long COVID ‘expotype’ within the P4O2 COVID-19 study J.C.S. Holtjer, L. Houweling, L.D. Bloemsma, M.E.B. Cornelissen, A.H. Maitland-Van der Zee, L. Portengen, S. Kakhaia, R.C.H. Vermeulen, G.S. Downward, the P4O2 consortium [Line breaks added] Highlights • First study to...
  12. forestglip

    Global Prevalence of Long COVID, its Subtypes and Risk factors: An Updated Systematic Review and Meta-Analysis, 2025, Hou et al.

    Now published: Global Prevalence of Long COVID, Its Subtypes, and Risk Factors: An Updated Systematic Review and Meta-analysis Yiren Hou, Tian Gu, Zhouchi Ni, Xu Shi, Megan L Ranney, Bhramar Mukherjee [Line breaks added] Background This mega-systematic review evaluated the global prevalence...
  13. forestglip

    Preprint Effect of Paxlovid Treatment on Long COVID Onset: An EHR-Based Target Trial Emulation from N3C, 2024, Preiss et al.

    Uncorrected proof published on PLOS Medicine: Effect of Paxlovid treatment during acute COVID-19 on Long COVID onset: An EHR-based target trial emulation from the N3C and RECOVER consortia [Line breaks added] Background Preventing and treating post-acute sequelae of SARS-CoV-2 infection...
  14. forestglip

    Protocol Assessing Neuroinflammation in Gulf War Illness Using Magnetic Resonance Spectroscopy, Younger

    The following newly released thesis looks like it might be the same study, though the details aren't exactly the same. Thesis Identifying the Neurobiological Substrates of Gulf War Illness, 2025, Jones
  15. forestglip

    Thesis Identifying the Neurobiological Substrates of Gulf War Illness, 2025, Jones

    I think this might be the same study as the trial registration in this thread, though the details look a little different. Assessing Neuroinflammation in Gulf War Illness Using Magnetic Resonance Spectroscopy, Younger
  16. forestglip

    Thesis Identifying the Neurobiological Substrates of Gulf War Illness, 2025, Jones

    Identifying the Neurobiological Substrates of Gulf War Illness by Chloe Jones Jarred Younger, Committee Chair; Adam Goodman; Maxine Krengel; Virendra Mishra; Robert Sorge [Line breaks added] Abstract Gulf War Illness (GWI) affects approximately 30% of veterans who served in the 1991 Persian...
  17. forestglip

    Evaluating the Causal Role of Genetically Inferred Immune Cells and Inflammatory Cytokines on ME/CFS, 2025, Duan et al

    Studies from the first few pages of results on Google Scholar (and one found as a citation) related to NKT cells in people with ME/CFS: - Abnormal T-Cell Activation And Cytotoxic T-Cell Frequency Discriminates Symptom Severity In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, 2025...
  18. forestglip

    A tablet-based intervention study to alleviate cognitive and psychological symptoms in patients with post-Covid-19 condition, 2025, Leitner et al.

    It's just assumed that participants in an unblinded trial filling out a questionnaire differently means their symptoms improved. No mention of the possibility of bias related to subjective outcomes in the limitations.
  19. forestglip

    Preprint Initial findings from the DecodeME genome-wide association study of myalgic encephalomyelitis/chronic fatigue syndrome, 2025, DecodeMe Collaboration

    It looks like you can download summary stats on the GWAS Atlas website. I'm not sure if it has data from exactly the same study you linked, but it has several for depression. For example, there's a depression trait which looks like it has NEGR1 as significant. Clicking the link next to "File"...
Back
Top Bottom